Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Trial Profile

Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AZURE
  • Most Recent Events

    • 25 May 2021 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Results assessing MAF biomarker for response prediction by using data from two studies including this study presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 07 Feb 2018 Results of a study assessing predictive role of serum bone biomarkers in identifying patients with a high risk of developing bone metastasis published in the Journal of the National Cancer Institute
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top